Biotech · Private company · Boston, MA, US
Inozyme Pharma, Inc.
SEC CIK 0001693011
Track this companyFree. Adds Inozyme Pharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Control Arm (Conventional Therapy)Phase 3 · Ectonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- INZ-701Phase 3 · Ectonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- INZ-701Phase 2 · ATP-Binding Cassette Subfamily C Member 6 DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- INZ-701Phase 2 · Gene MutationsClinicalTrials.gov · fetched Nov 12, 2026
- INZ-701Phase 1 · CalciphylaxisClinicalTrials.gov · fetched Nov 12, 2026
- No Intervention for this observational studyEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- No Intervention for this observational studyEctonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 DeficiencyTERMINATED · started Jul 25, 2024ClinicalTrials.gov NCT06302439 · fetched Nov 12, 2026
- ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 DeficiencyPHASE2 · TERMINATED · started Jun 19, 2024ClinicalTrials.gov NCT06462547 · fetched Nov 12, 2026
- SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney DiseasePHASE1 · COMPLETED · started Feb 12, 2024ClinicalTrials.gov NCT06283589 · fetched Nov 12, 2026
- The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 DeficiencyPHASE3 · TERMINATED · started Nov 5, 2023ClinicalTrials.gov NCT06046820 · fetched Nov 12, 2026
- The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 DeficiencyPHASE1 · TERMINATED · started Jun 25, 2023ClinicalTrials.gov NCT05734196 · fetched Nov 12, 2026
- Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 DeficiencyCOMPLETED · started Jun 28, 2022ClinicalTrials.gov NCT05050669 · fetched Nov 12, 2026
- Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXEPHASE1_PHASE2 · COMPLETED · started Apr 11, 2022ClinicalTrials.gov NCT05030831 · fetched Nov 12, 2026
- Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 DeficiencyPHASE1_PHASE2 · COMPLETED · started Nov 21, 2021ClinicalTrials.gov NCT04686175 · fetched Nov 12, 2026
- Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 DeficiencyCOMPLETED · started May 6, 2020ClinicalTrials.gov NCT04372446 · fetched Nov 12, 2026
- Natural History Study: ENPP1 Deficiency or the Early-Onset Form of ABCC6 DeficiencyCOMPLETED · started Dec 5, 2018ClinicalTrials.gov NCT07745179 · fetched Nov 12, 2026
SEC filings9
- 8-K · 8-KSEC EDGAR · filed Jul 1, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 2, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 16, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 10, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 10, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 10, 2025 · fetched Nov 12, 2026